A novel cycloalkylamine salt of 2-(1-hydroxypentyl)benzoate

CN116262698BActive Publication Date: 2026-05-26CHENGDU SHIBEIKANG BIOLOGICAL MEDICINE TECH CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN Β· China
Patent Type
Patents(China)
Current Assignee / Owner
CHENGDU SHIBEIKANG BIOLOGICAL MEDICINE TECH CO LTD
Filing Date
2023-03-22
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

Existing butylphthalide drugs suffer from poor water solubility, low solubility, insufficient efficacy, and difficult preparation processes when treating ischemic cardiovascular and cerebrovascular diseases, which limits their clinical application. Furthermore, there is a lack of intravenous injection drugs with high safety and significant efficacy.

Method used

A novel cycloalkanamine salt of 2-(1-hydroxypentyl)benzoic acid was developed. By reacting with an organic solvent at a specific temperature to form a salt, a compound with good solid form and significant efficacy was formed, which is suitable for the preparation of pharmaceutical compositions such as tablets, capsules, large-volume infusions, small-volume injections, or granules.

Benefits of technology

The compound achieves a good solid form, enhances its antiplatelet aggregation effect and improves neurological symptoms, and has high solubility and stability. It is suitable for the prevention and treatment of ischemic heart and brain diseases, especially mild, moderate and severe acute ischemic stroke, and has high toxicity and good safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116262698B_ABST
    Figure CN116262698B_ABST
Patent Text Reader

Abstract

This invention relates to novel 2-(1-hydroxypentyl)benzoate, its preparation method, and its applications. Specifically, it relates to a cycloalkanamine 2-(1-hydroxypentyl)benzoate with the structure shown in Formula I, its preparation method, pharmaceutical compositions with the compound as the active ingredient, and the application of the compound in the treatment and / or prevention of ischemic cardiovascular and cerebrovascular diseases, especially mild, moderate, and severe acute ischemic stroke.
Need to check novelty before this filing date? Find Prior Art